Autolus Therapeutics plc (AUTL) Institutional Ownership

Ownership Summary

Autolus Therapeutics plc (NASDAQ:AUTL) showed up in the 13F filings of 84 institutional investors as of March 2026.

• These investors held 50.5% of outstanding shares in March 2026, down from 53.7% in December 2025.
• They decreased total shares held in Autolus Therapeutics by -4.75% from the prior quarter, while the number of investors in AUTL decreased 13.4% year over year.
• Of these 84 holders, 31 added to their stakes in Autolus Therapeutics, 31 trimmed positions, and 22 made no changes.
• The aggregate institutional position in Autolus Therapeutics amounted to 134.44Mn shares as of March 2026, down by 6.71Mn shares quarter on quarter, and down 33.93Mn shares year over year.
• MAK CAPITAL ONE LLC holds the largest position in AUTL at 33.62Mn shares as of March 31, 2026, or 12.63% of shares outstanding.
• Leading buyers of Autolus Therapeutics shares for the quarter ending March 2026 were MAK CAPITAL ONE LLC (3.62Mn), BALYASNY ASSET MANAGEMENT L.P. (971.69K), Marex Group plc (542.86K), UBS Group AG (428.68K), MILLENNIUM MANAGEMENT LLC (204.73K).
• The largest sellers of Autolus Therapeutics for the quarter ending March 2026 were Laurion Capital Management LP (3.32Mn), BlackRock, Inc. (2.21Mn), ACADIAN ASSET MANAGEMENT LLC (1.78Mn), ARMISTICE CAPITAL, LLC (1.7Mn), RENAISSANCE TECHNOLOGIES LLC (805.9K).
• Per Business Quant data, the top 10 holders of Autolus Therapeutics for the quarter ending March 2026 are MAK CAPITAL ONE LLC (33.62Mn), Blackstone Inc. (20.49Mn), Syncona Portfolio Ltd (16.64Mn), ARMISTICE CAPITAL, LLC (15.8Mn), Tetragon Partners GP Ltd (9.5Mn), SCHRODER INVESTMENT MANAGEMENT GROUP (9.49Mn), Frazier Life Sciences Management, L.P. (4.45Mn), BNP Paribas Asset Management Holding S.A. (3.36Mn), Laurion Capital Management LP (3.32Mn), RENAISSANCE TECHNOLOGIES LLC (2.3Mn).